Progesterone in Women with Recurrent Miscarriages: Author Reply

Coomarasamy, Aravinthan; Williams, Helen; Rai, Raj

DOI:

[10.1056/NEJMc1600491](https://doi.org/10.1056/NEJMc1600491)

License:

None: All rights reserved

Document Version

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Coomarasamy, A, Williams, H & Rai, R 2016, 'Progesterone in Women with Recurrent Miscarriages: Author Reply', *New England Journal of Medicine*, vol. 373, pp. 894. <https://doi.org/10.1056/NEJMc1600491>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Checked for eligibility: 03/03/2016

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Progesterone in Women with Recurrent Miscarriages

TO THE EDITOR: In summarizing their well-executed randomized trial, Progesterone in Recurrent Miscarriages (PROMISE), Coomarasamy et al. (Nov. 26 issue)¹ state that there is no evidence of benefit from progesterone supplementation “in the first trimester” of pregnancy among women who have had three or more miscarriages. We wish to clarify three points. First, the trial did not address progesterone supplementation in women with coexisting subfertility. Nearly 33% of the women screened for the trial were excluded because of subfertility (515 of 1568 women). Second, because progesterone plays a key role in the implantation of the embryo, benefit from supplementation may be realized if progesterone is administered before and at the time of implantation. In women undergoing fertility treatments, it is common to administer progesterone before and at the time of implantation,² but in the trial by Coomarasamy et al., administration began after implantation. Third, a short luteal phase (<10 days) is associated with a lower probability of clinical pregnancy, and it may also be associated with miscarriage.^{3,4} The correction of a luteal-phase defect before implantation may improve the chance of ongoing pregnancy. The initiation of progesterone supplementation before pregnancy testing in women with subfertility, luteal-phase defect, or both deserves further investigation to determine whether it would increase the chance of successful implantation and ongoing pregnancy.

Paul A. Carpentier, M.D.

International Institute for Restorative Reproductive Medicine
of America
Gardner, MA
pcarp.md@verizon.net

Joseph B. Stanford, M.D.

University of Utah School of Medicine
Salt Lake City, UT

Phil C. Boyle, M.B., B.Ch., B.A.O.

International Institute for Restorative Reproductive Medicine
Dublin, Ireland

No potential conflict of interest relevant to this letter was reported.

1. Coomarasamy A, Williams H, Truchanowicz E, et al. A randomized trial of progesterone in women with recurrent miscarriages. *N Engl J Med* 2015;373:2141-8.

2. Mesen TB, Young SL. Progesterone and the luteal phase: a requisite to reproduction. *Obstet Gynecol Clin North Am* 2015; 42:135-51.

3. Schliep KC, Mumford SL, Hammoud AO, et al. Luteal phase deficiency in regularly menstruating women: prevalence and overlap in identification based on clinical and biochemical diagnostic criteria. *J Clin Endocrinol Metab* 2014;99:E1007-14.

4. Fritz MA, Speroff L. Recurrent early pregnancy loss. In: Fritz MA, Speroff L, eds. *Clinical and gynecologic endocrinology and infertility*. 8th ed. Philadelphia: Lippincott Williams & Wilkins, 2015.

DOI: 10.1056/NEJMc1600491

THE AUTHORS REPLY: The purpose of the PROMISE trial was to examine the effects of progesterone supplementation in women who have had unexplained recurrent miscarriages. We did not include women with subfertility, and in fact women who did not conceive naturally within 1 year after recruitment were ineligible for randomization.

Our study focused on the use of progesterone in the first trimester of pregnancy and not in the luteal phase. The use of progesterone in the first trimester of pregnancy in women who have a history of unexplained recurrent miscarriages is widespread, although progesterone use in the luteal phase is rare. Our trial was designed to test current common practice. However, we agree that the question of whether to use progesterone in the luteal phase in women with unexplained recurrent miscarriages is important and requires further research. Such research will first require an improved understanding of luteal-phase defect; currently there are no accepted histologic, biochemical, proteomic, genomic, or other systems-biology-based techniques to identify luteal-phase defect, and a short cycle is only a crude marker of luteal-phase defect.

Arri Coomarasamy, M.B., Ch.B., M.D.

Helen Williams, B.Sc.

University of Birmingham
Birmingham, United Kingdom
a.coomarasamy@bham.ac.uk

Rajendra Rai, M.D.

Imperial College at St. Mary's Hospital Campus
London, United Kingdom

Since publication of their article, the authors report no further potential conflict of interest.

DOI: 10.1056/NEJMc1600491